Based on the report of Zhang et al. 201432, who demonstrated the transcription factors NFYa and NFYb control and upregulate PRMT5 expression in prostate cancer cells, we also determined levels of these transcription factors in DDL-218-treated human neuronal Kelly cells, which showed DDL-218 treatment only significantly increases NFYb mRNA compared to DMSO-treated cells (Fig. 1D). This evidence concerns the gene PRMT5 and prostate carcinoma.